Update on anaesthetic approach to pulmonary hypertension

European Journal of Anaesthesiology

Volumn 27, Issue 4, 2010, Pages 317-323

  Teo, Yee Wei ^a   Greenhalgh, Donna L ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Anaesthesia; Eisenmenger syndrome; Pulmonary hypertension

Indexed keywords

ADRENALIN; AMBRISENTAN; AMLODIPINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DILTIAZEM; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; HEPARIN; ILOPROST; LEVOSIMENDAN; MILRINONE; NIFEDIPINE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; UNIPROST; VASOPRESSIN; ANTIHYPERTENSIVE AGENT;

ANEMIA; ANESTHESIST; CENTRAL VENOUS PRESSURE; CONTINUOUS INFUSION; DOPPLER ECHOCARDIOGRAPHY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; EISENMENGER COMPLEX; ENDARTERECTOMY; EPIDURAL ANESTHESIA; EXERCISE; GENERAL ANESTHESIA; HEART CATHETERIZATION; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; HYPOXIA; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG HEMODYNAMICS; OXYGEN THERAPY; PARADOXICAL EMBOLISM; PATHOGENESIS; PATIENT MONITORING; PERIOPERATIVE PERIOD; PEROPERATIVE CARE; POLYCYTHEMIA; PREOPERATIVE EVALUATION; PULMONARY HYPERTENSION; PULSE OXIMETRY; REGIONAL ANESTHESIA; REVIEW; SINUS RHYTHM; SPINAL ANESTHESIA; SURGICAL RISK; SYSTEMIC VASCULAR RESISTANCE; TERATOGENICITY; THROMBOCYTE AGGREGATION; TIDAL VOLUME; VASODILATATION; ANESTHESIA; CLASSIFICATION; CLINICAL PROTOCOL; HYPERTENSION, PULMONARY; PROCEDURES; RISK ASSESSMENT;

ANESTHESIA; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL PROTOCOLS; EISENMENGER COMPLEX; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; HYPERTENSION, PULMONARY; MONITORING, INTRAOPERATIVE; PERIOPERATIVE CARE; PROSTAGLANDINS I; RISK ASSESSMENT;

EID: 77951983142     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e328335474e     Document Type: Review

References (52)

1. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34:888-894.
2. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:14S-34S.
3. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25:2243-2278.
4. Ramakrishna G, Sprung J, Ravi BS, et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005; 45:1691-1699.
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl):S43-S54.
6. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75.
7. Langleben D, Dupuis J, Hirsch A, et al. Pulmonary endothelin- 1 clearance in human pulmonary arterial hypertension. Chest 2005; 128 (6 suppl):622S.
8. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-221.
9. Dorfmüller P, Perros F, Balabanian K, HumbertM. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22:358-363.
10. Welsh CH, Hassell KL, Badesch DB, et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110:710-717.
11. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105-3111.
12. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023-1030.
13. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:78S-92S.
14. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115:343-349.
15. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53:1573-1619.
16. Rich S, Kaufmann E, Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81.
17. McLaughlin VV, Shillington A, RichS. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482.
18. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-788.
19. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
20. Galiè N, Ghofrani HA, Torbicki A, et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157. (Pubitemid 41653106)
21. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of nonpulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl):S85-S96.
22. Stolz D, Rasch H, Linka A, et al. A randomized, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32:619-628.
23. Blaise G, Langleben D, HubertB. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology 2003; 99:1415-1432.
24. Zamanian RT, Haddad F, Doyle RL, Weinacker AB Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007; 35:2037-2050.
25. Roberts DH, Lepore JJ, Maroo A, et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001; 120:1547-1555.
26. Piazza G, Goldhaber S.Z. The acutely decompensated right ventricle: pathways for diagnosis and management. Chest 2005; 128:1836-1852.
27. Vizza CD, Rocca GD, Roma AD, et al. Acute hemodynamic effects of inhaled nitric oxide, dobutamine, and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care 2001; 5:355-361.
28. Chen EP, Bittner HB, Davis RD Jr, et al. Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg 1997; 63:814-821.
29. Khazin V, Kaufman Y, Zabeeda D, et al. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth 2004; 18:156-159.
30. Holloway EL, Polumbo RA, HarrisonD.C. Acute circulatory effects of dopamine in patients with pulmonary hypertension. Br Heart J 1975; 37:482-485.
31. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297:1883-1891.
32. Kleber FX, Bollmann T, Borst MM, et al. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol 2009; 49:109-115.
33. Cavusoglu Y, Beyaztas A, Birdane A, AtaN. Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases. J Cardiovasc Med (Hagerstown) 2009; 10:503-507.
34. Beck JR, Mongero LB, Kroslowitz RM, et al. Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after highrisk cardiac surgery. Perfusion 1999; 14:37-42.
35. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173-1174.
36. Hache M, Denault AY, Belisle S, et al. Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth 2001; 48:924-929.
37. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004; 127:1058-1067.
38. Schroeder RA, Wood GL, Plotkin JS, KuoP.C. Intraoperative use of inhaled PGI2 for acute pulmonary hypertension and right ventricular failure. Anesth Analg 2000; 91:291-295.
39. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, et al. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 1998; 114:780-786.
40. Wang H, Gong M, Zhou B, DaiA. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 2009; 26:462-468.
41. Haraldsson SA, Kieler-Jensen N, RickstenS.E. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93:1439-1445.
42. Kwak YL, Lee CS, Park YH, et al. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension. Anaesthesia 2002; 57:9-14.
43. Smith AM, Elliot CM, Kiely DG, Channer K.S. The role of vasopressin in cardiorespiratory arrest and pulmonary hypertension. QJM 2006; 99:127-133.
44. Price LC, Forrest P, Sodhi V, et al. Use of vasopressin after caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth 2007; 99:552-555.
45. Braun EB, Palin CA, Hogue C.W. Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol. Anesth Analg 2004; 99:36-37.
46. Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J AmColl Cardiol 2009; 54 (1 Suppl):S67-S77.
47. Boeken U, Feindt P, Litmathe J, et al. Intraaortic balloon pumping in patients with right ventricular insufficiency after cardiac surgery: parameters to predict failure of IABP support. Thorac Cardiovasc Surg 2009; 57:324-328.
48. Nordhaug D, Steensrud T, Muller S, et al. Intraaortic balloon pumping improves hemodynamics and right ventricular efficiency in acute ischemic right ventricular failure. Ann Thorac Surg 2004; 78:1426-1432.
49. Wood P. The Eisenmenger syndrome. BMJ 1958; 2:701-709.
50. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebocontrolled study. Circulation 2006; 114:48-54.
51. Chau EM, Fan KY, ChowW.H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120:301-305.
52. Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003; 91:632-635.